表紙
市場調查報告書

全球排名前25名的麻醉藥製造商 (2020年):Novartis、Mylan、Teva、Merck等

Top 25 Anaesthesia Drugs Manufacturers 2020: Novartis, Mylan, Teva, Merck and Other Companies

出版商 Visiongain Ltd 商品編碼 927901
出版日期 內容資訊 英文 155 Pages
商品交期: 最快1-2個工作天內
價格
全球排名前25名的麻醉藥製造商 (2020年):Novartis、Mylan、Teva、Merck等 Top 25 Anaesthesia Drugs Manufacturers 2020: Novartis, Mylan, Teva, Merck and Other Companies
出版日期: 2020年01月03日內容資訊: 英文 155 Pages
簡介

預估全球麻醉藥市場將於2024年達118億美元規模,於2019∼2024年間以3.9%的CAGR推移。按領域來看,局部麻醉藥部門佔最大市場占比。

本報告研究全球25家麻醉藥市場領導企業,彙整各家企業簡介、主力產品、財務分析、業績動向、近期業務發展情況等,並分析市場整體基本結構、主要推動及阻礙因素、具前景PIPELINE產品及臨床動向、其他主要產業動向等情報。

第1章 分析概要

第2章 麻醉藥概要

  • 麻醉為何?
    • 麻醉藥類型
  • 麻醉藥風險與副作用
    • 局部的副作用
    • 一般的副作用
  • 麻醉藥流行病學
  • 人文經濟負擔
    • 死亡率
    • 發病率
    • 經濟影響

第3章 全球麻醉藥市場:概要

第4章 全球麻醉藥市場主要藥劑

  • 異丙酚(Diprivan)
  • 七氟烷(Sojourn、Ultane)
  • Remifentanil
  • Midazolam
  • 利多卡因
  • Ropivacaine

第5章 市場成長推動因素

  • 外科手術件數增加
  • 美容整形手術增加
  • 專用的ICD-10碼 (國際疾病分類)
  • 對全身麻醉藥的需求
  • 研發投資的增額
  • 醫療電力產品的進步
  • 老年人口的增加

第6章 市場課題

  • 醫療整合
  • 嚴格監管準則
  • 缺乏大型、前瞻性、合作性結果研究

第7章 市場趨勢

  • 尖端技術的進步
  • 市場內部的主要企業策略合作
  • 由於領導企業的投資增加,發展中國家的的醫療部門擴大
  • 藥物傳輸方法的進步
  • 改善手術室麻醉方法的新藥缺乏
  • 麻醉相關死亡率、發病率之安全性統計改善展望
  • 居家醫療保健的上升趨勢

第8章 PIPELINE分子

  • 具前景PIPELINE分子候補
    • Phase IV 分子
    • Phase III 分子
    • Phase I 分子

第9章 全球麻醉藥市場代表企業 (2018年)

  • Novartis AG
    • 企業概要
    • 企業最新趨勢
    • 業務部門
    • 產品投資組合
    • 業績
  • Mylan N.V.
  • Teva Pharmaceuticals Industries Limited AG
  • Merck & Co., Inc.
  • Pacira Pharmaceuticals, Inc.,
  • Hikma Pharmaceuticals. plc
  • Glaxosmithkine plc
  • Aspen Pharmacare Holdings Limited
  • Endo International plc (Endo International)
  • Nuvo Pharmaceuticals
  • Lannett
  • Nichi-Iko Pharmaceutical Co., Ltd (Sagent Pharmaceuticals)
  • Jiangsu Hengrui Medicine
  • Mydent International
  • Primex Pharmaceuticals AG
  • Fresenius Kabi AG
  • Johnson and Johnson
  • Baxter International Inc.
  • Abbott Laboratories
  • AstraZeneca plc
  • F. Hoffman-La Roche AG
  • AbbVie Inc.
  • B. Braun Melsungen AG
  • Eisai Co., Ltd.
  • Boehringer Ingelheim GmbH

第10章 結論

目錄
Product Code: PHA0645

The global anaesthesia drugs market is expected to reach $11.8bn in 2024 and is estimated to grow at a CAGR of 3.9% from 2019-2024. The local anaesthesia segment accounted for the largest share in the anaesthesia drugs market in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 155-page report you will receive 67 tables and 83 figures - all unavailable elsewhere.

The 155-page report provides clear detailed insight into the top 25 anaesthesia drugs manufacturers. Discover the key drivers and challenges affecting the market.

Report Scope

Profiles of leading anaesthesia drugs manufacturers:

  • Abbott Laboratories
  • AbbVie
  • Aspen Pharmacare
  • AstraZeneca
  • B. Braun Melsungen AG
  • Baxter International
  • Boehringer Ingelheim
  • Eisai
  • Endo International
  • Fresenius Kabi AG
  • GlaxoSmithKline
  • Hikma Pharmaceuticals
  • Jiangsu Hengrui Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • Lannett
  • Merck
  • Other companies

The report provides information and discussion on:

  • Company overview & analysis
  • Product offerings
  • Financial information
  • Strategic developments
  • This report discusses factors that drive and challenge the anaesthesia drugs market. Moreover, this report discusses the trends in anaesthesia drugs market.
  • This report discusses the leading drugs and potential molecules in the pipeline.

Key questions answered by this report:

  • What are the drivers and restraints of the anaesthesia drugs market?
  • Who are the leading anaesthesia drugs manufacturers?
  • What are their products, developmental candidates and therapeutic applications?
  • What is the status of the clinical trials they are undergoing?
  • What are the latest news and developments from those companies?

Visiongain's study is intended for anyone requiring commercial analyses for the Top 25 Anaesthesia Drugs Manufacturers 2020. You find data, trends and predictions.

Buy our report today Top 25 Anaesthesia Drugs Manufacturers 2020: Novartis, Mylan, Teva, Merck and Other Companies.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Why You Should Read This Report
  • 1.2 How This Report Delivers
  • 1.3 Key Questions Answered by This Analytical Report Include:
  • 1.4 Who is This Report For?
  • 1.5 Methodology
    • 1.5.1 Primary Research
    • 1.5.2 Secondary Research
    • 1.5.3 Market Evaluation & Forecasting Methodology
  • 1.6 Frequently Asked Questions (FAQ)
  • 1.7 Associated Visiongain Reports
  • 1.8 About Visiongain

2. Introduction to Anaesthetic Drugs

  • 2.1 What is an Anaesthesia?
    • 2.1.1 Types of Anaesthetics
      • 2.1.1.1 General Anaesthetics
      • 2.1.1.2 Local Anaesthetics
      • 2.1.1.3 Sedation
  • 2.2 What are the Risk and Side Effects of Anaesthesia Drugs?
    • 2.2.1 Localized side effects
    • 2.2.2 General side effects
  • 2.3 Epidemiology of Anaesthetic Drugs
  • 2.4 Humanistic and Economic Burden
    • 2.4.1 Mortality
    • 2.4.2 Morbidity
    • 2.4.3 Economic Impact

3. Introduction to the Global Anaesthesia Drugs Market

4. Leading Drugs in the Global Anaesthesia Drugs Market

  • 4.1 Propofol (Diprivan)
  • 4.2 Sevoflurane (Sojourn, Ultane)
  • 4.3 Remifentanil
  • 4.4 Midazolam
  • 4.5 Lidocaine
  • 4.6 Ropivacaine

5. Market Growth Drivers

  • 5.1 Increasing incidence of surgeries
  • 5.2 Increasing cosmetic surgeries
  • 5.3 Designated ICD-10 Code
  • 5.4 Demand for general anaesthesia drugs
  • 5.5 Increased investment in R&D
  • 5.6 Advancements in medical power supply products
  • 5.7 Rise in Geriatric population

6. Market Challenges

  • 6.1 Healthcare consolidation
  • 6.2 Stringent Regulatory Guidelines
  • 6.3 Paucity of large, prospective and collaborative outcome studies

7. Market Trends

  • 7.1 Advances in modern technologies
  • 7.2 Strategic alliances among key players in the market
  • 7.3 Expansion of healthcare sector in developing countries due to growing investments by major players
  • 7.4 Advancements in drug delivery methods
  • 7.5 Paucity of new drugs to change the practice of operating room Anaesthesia
  • 7.6 Expect improved safety statistics regarding anaesthesia mortality and morbidity
  • 7.7 Rising trend of home healthcare

8. Pipeline Molecules

  • 8.1 Promising Potential Pipeline Molecules
    • 8.1.1 Phase IV Molecules
      • 8.1.1.1 Exparel (Bupivacaine Liposome)
    • 8.1.2 Phase III Molecules
      • 8.1.2.1 Remimazolam (CNS 7056)
    • 8.1.3 Phase I Molecules
      • 8.1.3.1 Cyclopropyl-methoxycarbonyl metomidate (ABP-700)
      • 8.1.3.2 Carboetomidate
      • 8.1.3.3 JM-1232 (-) (MR04A3)
      • 8.1.3.4 Propofol
      • 8.1.3.5 PF0713
      • 8.1.3.6 Fospropofol
      • 8.1.3.7 AZD-3043 (TD4756)

9. Leading Companies in Global Anaesthetic Drugs Market, 2018

  • 9.1. Novartis AG
    • 9.1.1. Company overview
    • 9.1.2. Company snapshot
    • 9.1.3. Operating business segments
    • 9.1.4. Product portfolio
    • 9.1.5. Business performance
  • 9.2. Mylan N.V.
    • 9.2.1. Company overview
    • 9.2.2. Company snapshot
    • 9.2.3. Operating business segments
    • 9.2.4. Product portfolio
    • 9.2.5. Business performance
  • 9.3. Teva Pharmaceuticals Industries Limited AG
    • 9.3.1. Company overview
    • 9.3.2. Company snapshot
    • 9.3.3. Operating business segments
    • 9.3.4. Product portfolio
    • 9.3.5. Business performance
  • 9.4. Merck & Co., Inc.
    • 9.4.1. Company overview
    • 9.4.2. Company snapshot
    • 9.4.3. Operating business segments
    • 9.4.4. Product portfolio
    • 9.4.5. Business performance
  • 9.5. Pacira Pharmaceuticals, Inc.,
    • 9.5.1. Company overview
    • 9.5.2. Company snapshot
    • 9.5.3. Product portfolio
    • 9.5.4. Business performance
  • 9.6. Hikma Pharmaceuticals. plc
    • 9.6.1. Company overview
    • 9.6.2. Company snapshot
    • 9.6.3. Operating business segments
    • 9.6.4. Product portfolio
    • 9.6.5. Business performance
  • 9.7. Glaxosmithkine plc
    • 9.7.1. Company overview
    • 9.7.2. Company snapshot
    • 9.7.3. Operating business segments
    • 9.7.4. Product portfolio
    • 9.7.5. Business performance
  • 9.8. Aspen Pharmacare Holdings Limited
    • 9.8.1. Company overview
    • 9.8.2. Company snapshot
    • 9.8.3. Operating business segments
    • 9.8.4. Product portfolio
    • 9.8.5. Business performance
    • 9.8.6. Key strategic moves and development
  • 9.9. Endo International plc (Endo International)
    • 9.9.1. Company overview
    • 9.9.2. Company snapshot
    • 9.9.3. Operating business segments
    • 9.9.4. Product portfolio
    • 9.9.5. Business performance
  • 9.10. Nuvo Pharmaceuticals
    • 9.10.1. Company overview
    • 9.10.2. Company snapshot
    • 9.10.3. Product portfolio
    • 9.10.4. Business performance
  • 9.11. Lannett
    • 9.11.1. Company overview
    • 9.11.2. Company snapshot
    • 9.11.3. Operating business segment
    • 9.11.4. Product portfolio
    • 9.11.5. Business performance
  • 9.12. Nichi-Iko Pharmaceutical Co., Ltd (Sagent Pharmaceuticals)
    • 9.12.1. Company overview
    • 9.12.2. Company snapshot
    • 9.12.3. Operating business segment
    • 9.12.4. Product portfolio
    • 9.12.5. Business performance
  • 9.13. Jiangsu Hengrui Medicine
    • 9.13.1. Company overview
    • 9.13.2. Company snapshot
    • 9.13.3. Operating business segment
    • 9.13.4. Product portfolio
    • 9.13.5. Business performance
  • 9.14. Mydent International
    • 9.14.1. Company overview
    • 9.14.2. Company snapshot
    • 9.14.3. Operating business segment
    • 9.14.4. Product portfolio
    • 9.14.5. Business performance
  • 9.15. Primex Pharmaceuticals AG
    • 9.15.1. Company overview
    • 9.15.2. Company snapshot
    • 9.15.3. Product portfolio
    • 9.15.4. Business performance
  • 9.16. Fresenius Kabi AG
    • 9.16.1. Company overview
    • 9.16.2. Company snapshot
    • 9.16.3. Operating business segments
    • 9.16.4. Product portfolio
    • 9.16.5. Business performance
  • 9.17. Johnson and Johnson
    • 9.17.1. Company overview
    • 9.17.2. Company snapshot
    • 9.17.3. Operating business segments
    • 9.17.4. Product portfolio
    • 9.17.5. Business performance
    • 9.17.6. Key strategic move and development
  • 9.18. Baxter International Inc.
    • 9.18.1. Company overview
    • 9.18.2. Company snapshot
    • 9.18.3. Operating business segments
    • 9.18.4. Product portfolio
    • 9.18.5. Business performance
  • 9.19. Abbott Laboratories
    • 9.19.1. Company overview
    • 9.19.2. Company snapshot
    • 9.19.3. Operating business segments
    • 9.19.4. Product portfolio
    • 9.19.5. Business performance
  • 9.20. AstraZeneca plc
    • 9.20.1. Company overview
    • 9.20.2. Company snapshot
    • 9.20.3. Operating business segments
    • 9.20.4. Product portfolio
    • 9.20.5. Business performance
    • 9.20.6. Key strategic move and development
  • 9.21. F. Hoffman-La Roche AG
    • 9.21.1. Company overview
    • 9.21.2. Company snapshot
    • 9.21.3. Operating business segments
    • 9.21.4. Product portfolio
    • 9.21.5. Business performance
  • 9.22. AbbVie Inc.
    • 9.22.1. Company overview
    • 9.22.2. Company snapshot
    • 9.22.3. Operating business segments
    • 9.22.4. Product portfolio
    • 9.22.5. Business performance
  • 9.23. B. Braun Melsungen AG
    • 9.23.1. Company overview
    • 9.23.2. Company snapshot
    • 9.23.3. Operating business segments
    • 9.23.4. Product portfolio
    • 9.23.5. Business performance
    • 9.23.6. Key stratregic move and development
  • 9.24. Eisai Co., Ltd.
    • 9.24.1. Company overview
    • 9.24.2. Company snapshot
    • 9.24.3. Operating business segments
    • 9.24.4. Product portfolio
    • 9.24.5. Business performance
  • 9.25. Boehringer Ingelheim GmbH
    • 9.25.1. Company overview
    • 9.25.2. Company snapshot
    • 9.25.3. Operating business segments
    • 9.25.4. Product portfolio
    • 9.25.5. Business performance

10. Conclusions

  • Visiongain Report Sales Order Form
  • Associated Visiongain Reports
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 2.1 Type of Surgeries performed in 2010 and 2020 (%)
  • Table 8.1 Active Pipeline Molecules under Development for Anaesthesia Drugs
  • Table 9.1. Novartis: Company Snapshot
  • Table 9.2. Novartis: Operating Segments
  • Table 9.3. Novartis: Product Portfolio
  • Table 9.4. Mylan N.V.: Company Snapshot
  • Table 9.5. Mylan N.V.: Operating Segments
  • Table 9.6. Mylan N.V.: Product Portfolio
  • Table 9.7. Teva Pharmaceuticals Industries Limited: Company Snapshot
  • Table 9.8. Teva Pharmaceuticals Industries Limited: Operating Segments
  • Table 9.9. Teva Pharmaceuticals Industries Limited: Product Portfolio
  • Table 9.10. Merck: Company Snapshot
  • Table 9.11. Merck: Operating Segments
  • Table 9.12. Merck: Product Portfolio
  • Table 9.13. Pacira: Company Snapshot
  • Table 9.14. Pacira: Product Portfolio
  • Table 9.15. Hikma: Company Snapshot
  • Table 9.16. Hikma: Operating Segments
  • Table 9.17. Hikma: Product Portfolio
  • Table 9.18. GSK: Company Snapshot
  • Table 9.19. GSK: Operating Segments
  • Table 9.20. GSK: Product Portfolio
  • Table 9.21. Aspen: Company Snapshot
  • Table 9.22. Aspen: Main Operating Segments
  • Table 9.23. Aspen: Product Portfolio
  • Table 9.24. Endo International: Company Snapshot
  • Table 9.25. Endo International: Operating Segments
  • Table 9.26. Endo International: Product Portfolio
  • Table 9.27. Nuvo: Company Snapshot
  • Table 9.28. Nuvo: Product Portfolio
  • Table 9.29. Lannett: Company Snapshot
  • Table 9.30. Lannett: Product Portfolio
  • Table 9.31. Nichi: Company Snapshot
  • Table 9.32. Nichi: Product Portfolio
  • Table 9.33. Jiangsu: Company Snapshot
  • Table 9.34. Jiangsu: Product Portfolio
  • Table 9.35. Mydent: Company Snapshot
  • Table 9.36. Mydent: Product Portfolio
  • Table 9.37. Primex: Company Snapshot
  • Table 9.38. Primex: Product Portfolio
  • Table 9.39. Fresenius: Company Snapshot
  • Table 9.40. Fresenius: Operating Segments
  • Table 9.41. Fresenius: Product Portfolio
  • Table 9.42. Johnson and Johnson: Company Snapshot
  • Table 9.43. Johnson and Johnson: Operating Segments
  • Table 9.44. Johnson and Johnson: Product Portfolio
  • Table 9.45. Baxter: Company Snapshot
  • Table 9.46. Baxter: Operating Segments
  • Table 9.47. Baxter: Product Portfolio
  • Table 9.48. Abbott: Company Snapshot
  • Table 9.49. Abbott: Operating Segments
  • Table 9.50. Abbott: Product Portfolio
  • Table 9.51. AstraZeneca: Company Snapshot
  • Table 9.52. AstraZeneca: Product Portfolio
  • Table 9.53. Roche: Company Snapshot
  • Table 9.54. Roche: Operating Segments
  • Table 9.55. Roche: Product Portfolio
  • Table 9.56. AbbVie: Company Snapshot
  • Table 9.57. AbbVie: Product Portfolio
  • Table 9.58. B. Braun: Company Snapshot
  • Table 9.59. B. Braun: Operating Segments
  • Table 9.60. B. Braun: Product Portfolio
  • Table 9.61. Eisai: Company Snapshot
  • Table 9.62. Eisai: Product Portfolio
  • Table 9.63. Boehringer: Company Snapshot
  • Table 9.64. Boehringer: Operating Segments
  • Table 9.65. Boehringer: Product Portfolio

List of Figures

  • Figure 9.1. Novartis: Net Sales, 2016-2018 ($Million)
  • Figure 9.2. Novartis: Revenue Share by Segment, 2018 (%)
  • Figure 9.3. Novartis: Revenue Share by Geography, 2018 (%)
  • Figure 9.4. Novartis: SWOT Analysis
  • Figure 9.5. Mylan N.V.: Net Sales, 2015-2017 ($Million)
  • Figure 9.6. Mylan N.V.: Revenue Share by Geography, 2017 (%)
  • Figure 9.7. Mylan N.V.: SWOT Analysis
  • Figure 9.8. Teva Pharmaceuticals Industries Limited: Net Sales, 2015-2017 ($Million)
  • Figure 9.9. Teva Pharmaceuticals Industries Limited: Revenue Share by Segment, 2017 (%)
  • Figure 9.10. Teva Pharmaceuticals Industries Limited: Revenue Share by Geography, 2017 (%)
  • Figure 9.11. Teva Pharmaceuticals Industries Limited: SWOT Analysis
  • Figure 9.12. Merck: Net Sales, 2015-2017 ($Million)
  • Figure 9.13. Merck: Revenue Share by Segment, 2017 (%)
  • Figure 9.14. Merck: Revenue Share by Geography, 2017 (%)
  • Figure 9.15. Merck: SWOT Analysis
  • Figure 9.16. Pacira: Net Sales, 2015-2017 ($Million)
  • Figure 9.17. Pacira: Revenue Share by Geography, 2017 (%)
  • Figure 9.18. Pacira: SWOT Analysis
  • Figure 9.19. Hikma: Net Sales, 2015-2017 ($Million)
  • Figure 9.20. Hikma: Revenue Share by Geography, 2017 (%)
  • Figure 9.21. Hikma: SWOT Analysis
  • Figure 9.22. GSK: Net Sales, 2015-2017 ($Million)
  • Figure 9.23. GSK: Revenue Share by Segment, 2017 (%)
  • Figure 9.24. GSK: Revenue Share by Geography, 2017 (%)
  • Figure 9.25. GSK: SWOT Analysis
  • Figure 9.26. Aspen: Net Sales, 2017-2018 ($Million)
  • Figure 9.27. Aspen: Revenue Share by Segment, 2018 (%)
  • Figure 9.28. Aspen: Revenue Share by Geography, 2018 (%)
  • Figure 9.29. Aspen: SWOT Analysis
  • Figure 9.30. Endo International: Net Sales, 2016-2018 ($Million)
  • Figure 9.31. Endo International: Revenue Share by Segment, 2018 (%)
  • Figure 9.32. Endo International: SWOT Analysis
  • Figure 9.33. Nuvo: Net Sales, 2016-2017 ($Million)
  • Figure 9.34. Nuvo: Revenue Share by Geography, 2017 (%)
  • Figure 9.35. Nuvo: SWOT Analysis
  • Figure 9.36. Lannett: Net Sales, 2016-2018 ($Million)
  • Figure 9.37. Lannett: SWOT Analysis
  • Figure 9.38. Nichi: Net Sales, 2017-2018 ($Million)
  • Figure 9.39. Nichi: SWOT Analysis
  • Figure 9.40. Jiangsu: SWOT Analysis
  • Figure 9.41. Mydent: SWOT Analysis
  • Figure 9.42. Primex: SWOT Analysis
  • Figure 9.43. Fresenius: Net Sales, 2015-2017 ($Million)
  • Figure 9.44. Fresenius: Revenue Share by Segment, 2017 (%)
  • Figure 9.45. Fresenius: Revenue Share by Geography, 2017 (%)
  • Figure 9.46. Fresenius: SWOT Analysis
  • Figure 9.47. Johnson and Johnson: Net Sales, 2016-2018 ($Million)
  • Figure 9.48. Johnson and Johnson: Revenue Share by Segment, 2018 (%)
  • Figure 9.49. Johnson and Johnson: Revenue Share by Geography, 2018 (%)
  • Figure 9.50. Johnson and Johnson: SWOT Analysis
  • Figure 9.51. Baxter: Net Sales, 2016-2018 ($Million)
  • Figure 9.52. Baxter: Revenue Share by Segment, 2018 (%)
  • Figure 9.53. Baxter: Revenue Share by Geography, 2018 (%)
  • Figure 9.54. Baxter: SWOT Analysis
  • Figure 9.55. Abbott: Net Sales, 2016-2018 ($Million)
  • Figure 9.56. Abbott: Revenue Share by Segment, 2018 (%)
  • Figure 9.57. Abbott: Revenue Share by Geography, 2018 (%)
  • Figure 9.58. Abbott: SWOT Analysis
  • Figure 9.59. AstraZeneca: Net Sales, 2016-2018 ($Million)
  • Figure 9.60. AstraZeneca: Revenue Share by Segment, 2018 (%)
  • Figure 9.61. AstraZeneca: Revenue Share by Geography, 2018 (%)
  • Figure 9.62. AstraZeneca: SWOT Analysis
  • Figure 9.63. Roche: Net Sales, 2016-2018 ($Million)
  • Figure 9.64. Roche: Revenue Share by Segment, 2018 (%)
  • Figure 9.65. Roche: Revenue Share by Geography, 2018 (%)
  • Figure 9.66. Roche: SWOT Analysis
  • Figure 9.67. AbbVie: Net Sales, 2016-2018 ($Million)
  • Figure 9.68. AbbVie: Revenue Share by Segment, 2018 (%)
  • Figure 9.69. AbbVie: Revenue Share by Geography, 2018 (%)
  • Figure 9.70. Abbvie: SWOT Analysis
  • Figure 9.71. B. Braun: Net Sales, 2015-2017 ($Million)
  • Figure 9.72. B. Braun: Revenue Share by Segment, 2017 (%)
  • Figure 9.73. B. Braun: Revenue Share by Geography, 2017 (%)
  • Figure 9.74. B. Braun: SWOT Analysis
  • Figure 9.75. Eisai: Net Sales, 2016-2018 ($Million)
  • Figure 9.76. Eisai: Revenue Share by Geography, 2017 (%)
  • Figure 9.77. Eisai: SWOT Analysis
  • Figure 9.78. Boehringer: Net Sales, 2016-2017 ($Million)
  • Figure 9.79. Boehringer: Revenue Share by Segment, 2017 (%)
  • Figure 9.80. Boehringer: Revenue Share by Geography, 2017 (%)
  • Figure 9.81. Boehringer: SWOT Analysis
  • Figure 10.1 Anaesthesia market, by type (% share 2016 & 2028)
  • Figure 10.2 Anaesthesia market by route of administration (% share 2016 & 2028)

List of Companies and Organizations Mentioned in the Report:

  • Abbott Laboratories
  • AbbVie
  • Aspen Pharmacare Holdings Limited (Aspen)
  • AstraZeneca
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boehringer Ingelheim GmbH
  • DePuy Synthes
  • Eisai Co., Ltd.
  • Endo International plc
  • Fresenius Kabi AG
  • GlaxoSmithKline plc (GSK)
  • Hikma Pharmaceuticals PLC
  • International Society of Aesthetic Plastic Surgery (ISAPS)
  • Janssen Pharmaceuticals
  • Jiangsu Hengrui Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • Lannett
  • Merck & Co., Inc.
  • Mydent International, Inc.
  • Mylan
  • National Institute of Health (NIH)
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Novartis
  • Nuvo Pharmaceuticals Inc.
  • Nuvo Research Inc.
  • Pacira Pharmaceuticals
  • Primex Pharmaceuticals AG
  • Roche
  • Siamab Therapeutics, Inc.
  • Teva Pharmaceuticals
  • Thermo Fisher Scientific
  • World Health Organization